Jaguar health announces submission of clinical trial applications for crofelemer for the rare disease indications microvillus inclusion disease (mvid) and short bowel syndrome (sbs) in europe

Jaguar's novel plant-based prescription drug crofelemer has been granted orphan drug designation by the fda and the european medicines agency for both mvid and sbs san francisco, ca / accesswire / may 9, 2024 / jaguar health, inc. (nasdaq:jagx) ("jaguar") today announced that jaguar family companies napo pharmaceuticals ("napo") and napo therapeutics have submitted a clinical trial application (cta) to the italian and german health authorities to initiate a phase 2 clinical trial of jaguar's novel plant-based prescription drug crofelemer for treatment of short bowel syndrome (sbs) with intestinal failure in adults. napo therapeutics has also submitted a cta to aifa, the italian health authority, for the conduct of a clinical trial in pediatric patients with microvillus inclusion disease (mvid), and the approval request process is also underway for this trial in the united arab emirates with dubai health.
JAGX Ratings Summary
JAGX Quant Ranking